DelveInsight's "FABHALTA Market Size, Forecast, and Market Insight Report" highlights the details around FABHALTA, an oral ...

With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions like ...

With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions ...

have recommended reimbursement of Fabhalta in the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor 5,6 Novartis Pharmaceuticals Canada Inc.

MONTREAL, April 14, 2025 /CNW/ - Novartis Canada is pleased to announce that Fabhalta ® (iptacopan capsules) is now available across Canada for adult patients with paroxysmal nocturnal ...